Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1993 2
1994 5
1995 11
1996 16
1997 14
1998 11
1999 16
2000 19
2001 42
2002 71
2003 78
2004 132
2005 136
2006 154
2007 161
2008 209
2009 208
2010 184
2011 206
2012 201
2013 214
2014 221
2015 203
2016 169
2017 219
2018 222
2019 231
2020 271
2021 226
2022 176
2023 138
2024 59

Text availability

Article attribute

Article type

Publication date

Search Results

3,701 results

Results by year

Filters applied: . Clear all
Page 1
Alemtuzumab.
Frampton JE, Wagstaff AJ. Frampton JE, et al. Drugs. 2003;63(12):1229-43; discussion 1245-6. doi: 10.2165/00003495-200363120-00003. Drugs. 2003. PMID: 12790693 Review.
Alemtuzumab is an unconjugated, humanised, monoclonal antibody directed against the cell surface antigen CD52 on lymphocytes and monocytes. ...Combining alemtuzumab with fludarabine resulted in ORs >80%. In noncomparative studies in patients with previously untre …
Alemtuzumab is an unconjugated, humanised, monoclonal antibody directed against the cell surface antigen CD52 on lymphocytes and mono …
Alemtuzumab for the treatment of multiple sclerosis.
Evan JR, Bozkurt SB, Thomas NC, Bagnato F. Evan JR, et al. Expert Opin Biol Ther. 2018 Mar;18(3):323-334. doi: 10.1080/14712598.2018.1425388. Expert Opin Biol Ther. 2018. PMID: 29309202 Review.
Alemtuzumab is a monoclonal antibody that targets for the destruction CD52+ cells, particularly B and T cells. ...Expert opinion: Alemtuzumab is highly efficacious; more so than first line treatments but comparable to natalizumab. ...
Alemtuzumab is a monoclonal antibody that targets for the destruction CD52+ cells, particularly B and T cells. ...Expert opinion: …
Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis.
Syed YY. Syed YY. Drugs. 2021 Jan;81(1):157-168. doi: 10.1007/s40265-020-01437-2. Drugs. 2021. PMID: 33367970 Review.
Alemtuzumab (Lemtrada()) is an anti-CD52 monoclonal antibody approved in the EU for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS). ...Alemtuzumab has an acceptable tolerability profile, with infusion-associated reactions, infections an …
Alemtuzumab (Lemtrada()) is an anti-CD52 monoclonal antibody approved in the EU for the treatment of highly active relapsing-remittin …
[Alemtuzumab therapy 2017].
Biernacki T , Bencsik K , Sandi D , Vécsei L . Biernacki T , et al. Ideggyogy Sz. 2017 Nov 30;70(11-12):371-380. doi: 10.18071/isz.70.0371. Ideggyogy Sz. 2017. PMID: 29870645 Free article. Review. Hungarian.
The efficacy of alemtuzumab was proven in two phase III trials (CARE-MS I, II), where it was compared to subcutaneous interferon b-1a, administered three times weekly. In both studies alemtuzumab was superior to subcutaneous interferon b-1a in terms of relapse rate …
The efficacy of alemtuzumab was proven in two phase III trials (CARE-MS I, II), where it was compared to subcutaneous interferon b-1a …
Alemtuzumab as Treatment for Multiple Sclerosis.
Katsavos S, Coles A. Katsavos S, et al. Cold Spring Harb Perspect Med. 2018 Oct 1;8(10):a032029. doi: 10.1101/cshperspect.a032029. Cold Spring Harb Perspect Med. 2018. PMID: 29500306 Free PMC article. Review.
Alemtuzumab, the first monoclonal antibody to be used as a therapy and the first to be humanized, was introduced into the treatment of multiple sclerosis in 1991 after its successful use in hematology, oncology, and transplantation medicine. ...With the prerequisite of pat …
Alemtuzumab, the first monoclonal antibody to be used as a therapy and the first to be humanized, was introduced into the treatment o …
Alemtuzumab in renal transplantation. Reviews of literature and usage in the United Kingdom.
Chukwu CA, Spiers HVM, Middleton R, Kalra PA, Asderakis A, Rao A, Augustine T. Chukwu CA, et al. Transplant Rev (Orlando). 2022 Apr;36(2):100686. doi: 10.1016/j.trre.2022.100686. Epub 2022 Jan 31. Transplant Rev (Orlando). 2022. PMID: 35151219 Review.
Despite the many years of experience with alemtuzumab, its utilisation in the UK has remained relatively restrained. ...This review discusses the current use of alemtuzumab for immunosuppression induction in kidney transplantation. ...
Despite the many years of experience with alemtuzumab, its utilisation in the UK has remained relatively restrained. ...This review d …
Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.
Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr KM, Oreja-Guevara C, Stoliarov I, Zettl UK. Berger T, et al. CNS Drugs. 2017 Jan;31(1):33-50. doi: 10.1007/s40263-016-0394-8. CNS Drugs. 2017. PMID: 27882532 Free PMC article. Review.
Alemtuzumab (Lemtrada) is a humanized monoclonal antibody approved in more than 50 countries. ...Given these considerations, it is beneficial to gain insight into how alemtuzumab is being used in the real-world clinical setting. Here, we report recommendations from …
Alemtuzumab (Lemtrada) is a humanized monoclonal antibody approved in more than 50 countries. ...Given these considerations, it is be …
Alemtuzumab.
Bates D. Bates D. Int MS J. 2009 Sep;16(3):75-6. Int MS J. 2009. PMID: 19899240
When the CAMMS 223 trial was formally reported in the New England Journal of Medicine in October of 2008, huge interest was generated in the media, among people with multiple sclerosis (MS) and their relatives and friends. The suggestion that a therapy Campath-1H (now known as …
When the CAMMS 223 trial was formally reported in the New England Journal of Medicine in October of 2008, huge interest was generated in the …
Alemtuzumab (Campath 1-H).
Schaal AD. Schaal AD. Clin J Oncol Nurs. 2005 Oct;9(5):630-2. doi: 10.1188/05.CJON.630-632. Clin J Oncol Nurs. 2005. PMID: 16235592 Review.
Alemtuzumab is an exciting targeted therapy for patients with CD52-sensitive malignancies. ...The Cancer and Leukemia Group B is conducting a study using alemtuzumab as consolidation treatment for patients with B-CLL. The group also is conducting a phase I and II do …
Alemtuzumab is an exciting targeted therapy for patients with CD52-sensitive malignancies. ...The Cancer and Leukemia Group B is cond …
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.
Ruck T, Bittner S, Wiendl H, Meuth SG. Ruck T, et al. Int J Mol Sci. 2015 Jul 20;16(7):16414-39. doi: 10.3390/ijms160716414. Int J Mol Sci. 2015. PMID: 26204829 Free PMC article. Review.
Alemtuzumab has proven high efficacy in clinical phase II and III trials, where interferon beta-1a was used as active comparator. ...This review provides and analyses the current knowledge on the MOA of alemtuzumab. Most recent data on efficacy and safety of alem …
Alemtuzumab has proven high efficacy in clinical phase II and III trials, where interferon beta-1a was used as active comparator. ... …
3,701 results